AxoGen, Inc. (NASDAQ:AXGN) Stock Holdings Lifted by Sentry Investment Management LLC

Sentry Investment Management LLC increased its holdings in AxoGen, Inc. (NASDAQ:AXGN) by 9.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,368 shares of the medical equipment provider’s stock after acquiring an additional 1,483 shares during the period. Sentry Investment Management LLC’s holdings in AxoGen were worth $243,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. nVerses Capital LLC bought a new stake in shares of AxoGen during the 3rd quarter worth about $56,000. Koss Olinger Consulting LLC bought a new position in shares of AxoGen in the second quarter valued at about $75,000. Lazard Asset Management LLC raised its stake in shares of AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock worth $93,000 after acquiring an additional 2,671 shares during the last quarter. SG Americas Securities LLC acquired a new position in AxoGen during the 3rd quarter worth $227,000. Finally, Acadian Asset Management LLC acquired a new position in shares of AxoGen during the second quarter valued at $125,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. JMP Securities raised their target price on AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a report on Friday, August 9th. StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $15.00.

AxoGen Stock Performance

NASDAQ:AXGN opened at $14.20 on Tuesday. The firm has a market capitalization of $622.39 million, a PE ratio of -37.37 and a beta of 1.13. The company has a quick ratio of 2.32, a current ratio of 3.51 and a debt-to-equity ratio of 0.70. The stock’s 50-day simple moving average is $13.71 and its 200 day simple moving average is $9.95. AxoGen, Inc. has a twelve month low of $3.92 and a twelve month high of $15.23.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The business had revenue of $47.91 million during the quarter, compared to the consensus estimate of $43.27 million. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%. On average, analysts anticipate that AxoGen, Inc. will post -0.33 EPS for the current fiscal year.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.